| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_502bfc0709ea9ed74ef0d69764f0be2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16d115cc442b09b9566c069a875ee002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8d34065381a237a53c7449c3840b601
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c04a1ceffcd599c4b0beed9e46a6c35 |
| publicationDate |
2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DK-202000038-Y3 |
| titleOfInvention |
Liquid pharmaceutical composition |
| abstract |
The invention relates to novel liquid pharmaceutical compositions of adalimumab, which comprise adalimumab or a biosimilar agent thereof, a citrate buffer / system such as sodium citrate / citric acid and a sugar stabilizer such as trehalose. Such a combination of ingredients provides formulations with a stability (eg by storage or exposure to loads) which is comparable to or improved over those known in the art and with fewer ingredients. Such advances will promote the availability of adalimumab treatments at lower cost and extend the shelf life of pre-filled dispensers (eg pre-filled syringes), thus reducing unnecessary waste of the drug. |
| priorityDate |
2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |